TTLL9

Across TCGA pan-cancer cohorts, TTLL9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTLL9 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TTLL9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TTLL9 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, UCEC, and GBM are the cancer types where TTLL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.820	1.000	.018	10	view →
UCEC	OS	Median	All	0.820	1.000	.032	8	view →
GBM	OS	Median	All	0.924	0.826	.040	1	view →
HNSC	OS	Median	II,III,IV	1.000	0.921	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTLL9–PDAC (OS)

Open the PDAC breakdown →